Publications by authors named "Alan Cruess"

Claim this Profile
A
A fluorescein angiography-based computer-aided algorithm for assessing the retinal vasculature in diabetic retinopathy.
Amir Abbasnejad, Oren Tomkins-Netzer, Aaron Winter, Alon Friedman, Alan Cruess

Eye (Lond)· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response of Pediatric Choroidal Neovascularization to Anti-Vascular Endothelial Growth Factor.
Sunil Ruparelia, Aishwarya Sundaram, Mishari Dahrab, Chris Symonds, Alan Cruess

Cureus· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imaging Biomarkers and Their Impact on Therapeutic Decision-Making in the Management of Neovascular Age-Related Macular Degeneration.
David T Wong, Alan R Berger, Serge Bourgault, John Chen, Kevin Colleaux, Alan F Cruess

Ophthalmologica· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying gaps in patient access to diabetic screening eye examinations in Ontario: a provincially representative cross-sectional study.
Brian G Ballios, Teresa Park, Varun Chaudhary, Bernard Hurley, Stephen Kosar, Alan Cruess

Can J Ophthalmol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of intravitreal bevacizumab in Gram-positive and Gram-negative models of ocular inflammation.
J Daniel Lafreniere, James T Toguri, Rishi R Gupta, Arif Samad, Dan M O'Brien, Alan Cruess

Clin Exp Ophthalmol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies.
Paolo Lanzetta, Alan F Cruess, Salomon Y Cohen, Jason S Slakter, Todd Katz

Acta Ophthalmol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic Safety in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration: A Patient-Level Pooled Analysis.
Marco A Zarbin, Steven Francom, Susanna Grzeschik, Lisa Tuomi, Zdenka Haskova, Alan Cruess

Ophthalmol Retina· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Excerpt from the Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy.
Philip Hooper, Marie Carole Boucher, Alan Cruess, Keith G Dawson, Walter Delpero

Can J Ophthalmol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ranibizumab in Diabetic Macular Oedema - A Benefit-risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment.
Focke Ziemssen, Alan Cruess, Cornelia Dunger-Baldauf, Philippe Margaron, Howard Snow

Eur Endocrinol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VEGF-A is increased in exogenous endophthalmitis.
Mark E Seamone, Darrell R Lewis, Ian D Haidl, R Rishi Gupta, Daniel M O' Brien, Alan F Cruess

Can J Ophthalmol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory Factors Influencing Usage of Retinal Pharmaceuticals: A Look Both Home and Abroad.
Daniel E Croft, Charles C Wykoff, Stephan Michels, Usha Chakravarthy, Alan F Cruess

Am J Ophthalmol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal Treatment of Retinal Vein Occlusion: Canadian Expert Consensus.
Alan R Berger, Alan F Cruess, Filiberto Altomare, Varun Chaudhary, Kevin Colleaux

Ophthalmologica· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME.
Alan Berger, Tom Sheidow, Alan F Cruess, Jean Daniel Arbour, Anne-Sophie Courseau

Can J Ophthalmol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What percentage of patients presenting for routine eye examinations require referral for secondary care? A study of referrals from optometrists to ophthalmologists.
David Dobbelsteyn, Katherine McKee, Reece D Bearnes, Sujani N Jayanetti, David D Persaud, Alan F Cruess

Clin Exp Optom· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac issues of noncardiac drugs: the rising story of avastin in age-related macular degeneration.
Alan F Cruess, Nicholas Giacomantonio

Ophthalmologica· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contemporary management of diabetic retinopathy in Canada: from guidelines to algorithm guidance.
Philip Hooper, Marie-Carole Boucher, Kevin Colleaux, Alan Cruess, Mark Greve

Ophthalmologica· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines.
Peter K Kaiser, Alan F Cruess, Peter Bogaert, Kamlesh Khunti, Simon P Kelly

Graefes Arch Clin Exp Ophthalmol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An estimation of the worldwide economic and health burden of visual impairment.
Adam Gordois, Henry Cutler, Lynne Pezzullo, Keith Gordon, Alan Cruess

Glob Public Health· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration.
Alan F Cruess, Alan Berger, Kevin Colleaux, Mark Greve, Patricia Harvey

Can J Ophthalmol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
Peter K Kaiser, David S Boyer, Alan F Cruess, Jason S Slakter, Stefan Pilz

Ophthalmology· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Diabetic Retinopathy - executive summary.

Can J Ophthalmol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy.
Philip Hooper, Marie Carole Boucher, Alan Cruess, Keith G Dawson, Walter Delpero

Can J Ophthalmol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cost of vision loss in Canada. 1. Methodology.
Keith D Gordon, Alan F Cruess, Lorne Bellan, Scott Mitchell, M Lynne Pezzullo

Can J Ophthalmol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cost of vision loss in Canada. 2. Results.
Alan F Cruess, Keith D Gordon, Lorne Bellan, Scott Mitchell, M Lynne Pezzullo

Can J Ophthalmol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacologic management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation.
William Hodge, Allan Brown, Steve Kymes, Alan Cruess, Gord Blackhouse

Can J Ophthalmol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis